Search

Your search keyword '"Janssen, Harry L.A."' showing total 692 results

Search Constraints

Start Over You searched for: Author "Janssen, Harry L.A." Remove constraint Author: "Janssen, Harry L.A."
692 results on '"Janssen, Harry L.A."'

Search Results

1. Incidence and prevalence of primary biliary cholangitis in the Netherlands – A nationwide cohort study

2. Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction

3. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

6. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

10. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

13. REPLY: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB

14. SAT-200-YI Statin use is associated with liver fibrosis regression in the general population: a longitudinal analysis of The Rotterdam Study

17. THU-138 The male-to-female ratio among patients with primary biliary cholangitis depends on age

18. FRI-390 Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus

20. Incidence and prevalence of primary biliary cholangitis in the Netherlands – a nationwide cohort study

21. THU-100 Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis

22. FRI-200 Magnitude of steatotic liver disease before and after liver transplantation and the impact of immunosuppressive medication: a multidimensional study

23. FRI-363-YI Association between metabolic dysfunction, severity of liver fibrosis and fibrosis progression in patients with chronic hepatitis B-an individual patient data meta-analysis

24. THU-098 Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes

26. SAT-462-YI The interplay between steototic liver disease and viral infections: systematic review, meta-analysis and data synthesis

28. THU-120-YI The impact of ursodeoxycholic acid on biochemistry of patients with primary biliary cholangitis in a nationwide cohort

29. TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk

32. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

40. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

42. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

44. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants

45. Factors associated with knowledge and awareness of Hepatitis B in individuals of Chinese descent:Results from a mass point of care testing and outreach campaign in Toronto, Canada

46. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

47. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic [CD8.sup.+] T cells

49. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis

50. HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition

Catalog

Books, media, physical & digital resources